Cryo-Cell International, Inc.

CCEL · NYSE American · Stock · Healthcare
$4.05
-2.41% today
Delayed price,

What Cryo-Cell International does

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key facts

Sector
Healthcare
Industry
Medical Care Facilities
Market cap
$32.7M
P/E (ttm)
—
Forward P/E
202.5
Dividend yield
0.00%
Beta
0.59
Profit margin
-6.2%
Employees
72
Headquarters
Oldsmar, FL, United States
Exchange
NYSE American

Performance

1 Month
-8.0%
3 Months
+17.1%
6 Months
+17.7%
1 Year
-11.0%
5 Years
-67.3%
$2.7252-week range$4.90
Biggest setback — last 12 months
-36.3%
13 Oct 2025 → 22 Jun 2026
Fell from $4.55 to $2.90 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+57.2%
22 Jun 2026 → 17 Aug 2026
Ran from $2.90 to $4.56 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend
Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$3.27 (-19.3%)$4.05$5.02 (+23.9%)
3 Months$2.79 (-31.0%)$4.05$5.87 (+45.0%)
6 Months$2.40 (-40.9%)$4.05$6.85 (+69.1%)
12 Months$1.93 (-52.4%)$4.05$8.51 (+110.2%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 74.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent insider activity

Acquired 1,200,382 shares at $1.33 — PORTNOY DAVID, Chairman, Co-CEO · 2026-08-07
Acquired 7,500 shares at $3.10 — TAYMANS JILL M, VP Finance, CFO · 2026-05-29
Acquired 200,000 shares at $3.89 — PORTNOY DAVID, Chairman, Co-CEO · 2026-01-09
Acquired 30,000 shares at $3.54 — Mikulinsky Oleg, Chief Information Officer · 2026-01-09
Acquired 75,000 shares at $3.89 — Portnoy Mark L., Co-CEO · 2026-01-09
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.